Valvular & structural heart disease
Lipoprotein (a) Distribution in Aortic Stenosis Patients: Are Lp(a) Reducing Agents the Ultimate Solution?
Authors' conclusion
In this cross-sectional series of unselected AS patients followed in a valve clinic, only 1 in every 4 patients had a significantly elevated Lp(a) level. Novel Lp(a)-lowering therapies may have limited applicability to most patients with AS and highlight the need for further research into understanding the pathophysiology of AS and developing medical therapies targeting different pathways.
Study context
- Population
- Nonselected Canadian population of aortic stenosis (AS) patients seen in a specialized valve clinicpatients with Lp(a) levels measured
- Participants
- 162 participants
- Outcome
- Lp(a) level
Methodological detailsnonselected, specialized valve clinic
- Nonselected
- Specialized valve clinic
Main finding
As reported in the abstract
Mean Lp(a)
69 ± 79 nmol/L
Median Lp(a)
24 nmol/L, IQR: 19-91 nmol/L
Observational data: associations, not effects.
Further findings
High Lp(a) level (≥100 nmol/L)
- Patients with high Lp(a) level
- 39 patients (24%)
- High Lp(a) defined as ≥100 nmol/L as per the Canadian Cardiovascular Society's Lipid Guidelines
Mean Lp(a) and proportion of high Lp(a) by sex, age, or AS severity
- No differences with respect to sex, age, or AS severity
- all P > 0.20
Baseline characteristics
- Mean age
- 75 ± 10 years
- Female
- 43%
- Mean pressure gradient
- 29 ± 14 mm Hg
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →